Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593753 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL29866225 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL27657195 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL15271352 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL593754 | 1.00 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL11810215 | 0.89 | ADRB2 (0.73) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL4684534 | 0.89 | ADRA1A (0.71) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL594467 | 0.86 | ADRB2 (0.70) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL594466 | 0.86 | ADRB2 (0.70) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| Salmefamol SCHEMBL20285629 | 0.85 | ADRB2 (0.67) | ADRB2ADRB1ADRB3DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116136523-A | Separation detection method for formoterol powder fog agent content of budesonide fumarate | 苏州易合医药有限公司 | 2023-05-19 | — | — | CN | claimed |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2012-03-01 | — | — | US | claimed |
| CN-116136523-A | Separation detection method for formoterol powder fog agent content of budesonide fumarate | 苏州易合医药有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-110376313-B | Method for detecting impurities in formoterol fumarate or related preparation thereof | 广州健康元呼吸药物工程技术有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-2305635-B1 | FORMOTEROL TARTRATE, PROCESS AND POLYMORPH | SUNOVION PHARMACEUTICALS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2825525-B1 | NEW POLYMORPHIC FORM OF A LONG-ACTING BETA-2 ADRENOCEPTOR AGONIST | LESVI LABORATORIOS SL (ES) | 2018-04-25 | — | — | EP | disclosed |
| US-9499475-B2 | Process for the preparation of arformoterol or salt thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-9499475-B2 | Process for the preparation of arformoterol or salt thereof | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| CN-104220420-B | Novel polycrystal of long-acting beta-2 adrenoceptor agonist | 利斯维实验室有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-9309186-B2 | Polymorphic form of a long-acting beta-2 adrenoceptor agonist | LABORATORIOS LESVI S.L. (ES) | 2016-04-12 | — | — | US | disclosed |
| US-20160083334-A1 | PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2016-03-24 | — | — | US | disclosed |
| US-20090156862-A1 | Formoterol Tartrate Process and Polymorph | SEPRACOR INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-7479572-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479572-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20080114187-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SEPRACOR INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080114187-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | SEPRACOR INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-7342132-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342132-B2 | Formoterol tartrate process and polymorph | SEPRACOR INC. (US) | 2008-03-11 | — | — | US | disclosed |
| US-6071971-A | FOR TREATING PULMONARY DISORDERS | SEPRACOR INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-5965622-A | BRONCHODILATORS; HIGHLY SELECTIVE BETA 2-ADRENERGIC RECEPTOR AGONIST; RESPIRATORY DISORDERS, E.G. ASTHMA, BRONCHITIS; REDUCTION OF A PROTECTED NITRO DERIVATIVE; STEREOSPECIFIC | SEPRACOR INC. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156862-A1 | Formoterol Tartrate Process and Polymorph | ADRB1, ADRA1B, ADRA1A | ADRB2 5/4885ADRB1 1/4885ADRB3 7/4885 |
| US-20080114187-A1 | FORMOTEROL TARTRATE PROCESS AND POLYMORPH | ADRB1, ADRA1B, ADRA1A | ADRB2 5/4885ADRB1 1/4885ADRB3 7/4885 |
| US-20120053246-A1 | PURIFICATION PROCESS FOR PREPARING HIGHLY PURE ARFORMOTEROL TARTRATE SUBSTANTIALLY FREE OF DESFORMYL IMPURITY | ADRB1, ADRB2, ADRA1A | ADRB2 2/4885ADRB1 1/4885ADRB3 5/4885 |
| US-20160083334-A1 | PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF | AGT, AGTR1, REN | ADRB2 8/4885ADRB1 5/4885ADRB3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.